Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up

BACKGROUND: The nine-valent human papillomavirus (9vHPV) vaccine protects against infection and disease related to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The pivotal 36-month Phase III immunogenicity study of 9vHPV vaccine in 9- to 15-year-old girls and boys was extended to assess long-ter...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsson, Sven-Eric, Restrepo, Jaime Alberto, Reina, Julio Cesar, Pitisuttithum, Punnee, Ulied, Angels, Varman, Meera, Van Damme, Pierre, Moreira, Edson Duarte, Ferris, Daron, Block, Stanley, Bautista, Oliver, Gallagher, Nancy, McCauley, Jennifer, Luxembourg, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396911/
https://www.ncbi.nlm.nih.gov/pubmed/32659510
http://dx.doi.org/10.1016/j.pvr.2020.100203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396911/
https://www.ncbi.nlm.nih.gov/pubmed/32659510
http://dx.doi.org/10.1016/j.pvr.2020.100203

Ejemplares similares